Molecular Endocrinology, Vol 10, 14-23, Copyright © 1996 by Endocrine Society

ARTICLES

In vivo evidence for the generation of a glucocorticoid receptor-heat shock protein-90 complex incapable of binding hormone by the calmodulin antagonist phenoxybenzamine

YM Ning and ER Sanchez
Department of Pharmacology, Medical College of Ohio, Toledo 43699, USA.

The glucocorticoid receptor (GR) is a ligand-regulated transcription factor whose ability to bind hormone is thought to be dependent on association with the 90-kDa heat shock protein (hsp90). In the present study, we have generated a novel form of the GR, in which the receptor remains complexed to hsp90 but has lost its ability to bind hormone, by treatment of intact cells with the calmodulin (CaM) antagonist phenoxybenzamine (POBA). Treatment of these cells, mouse L929 cells stably transfected with the mouse mammary tumor virus-chloramphenicol acetyltransferase (MMTV-CAT) reporter construct, with increasing concentrations of POBA resulted in a concentration-dependent inhibition of dexamethasone (Dex)-induced CAT gene expression, with 100 microM POBA resulting in approximately 80% inhibition. This inhibitory effect of POBA was markedly reduced if POBA was added after a short incubation with Dex, suggesting that the primary effect of POBA was on hormone- induced transformation of the GR. Using a subcellular fractionation technique, POBA inhibition of CAT gene expression was found to correlate with an inhibition of Dex-induced GR nuclear translocation. However, inhibition of translocation was not the primary effect of POBA on the GR signal pathway, as POBA was found to reduce GR hormone- binding capacity after treatment of intact cells. The inhibitory effect of POBA on hormone-binding function correlated closely with the inhibitory effect of this drug on CAT gene expression and was not due to an oxidation of sulfhydryl groups, a condition known to reduce GR hormone-binding capacity. Incubation of cytosols from untreated cells with POBA did not decrease GR steroid-binding capacity, demonstrating that this inhibitory effect was not the result of a competitive antagonism at the ligand-binding site. Quantitation of GR protein in the cytosols of POBA-treated cells revealed that the decrease in steroid-binding function was not due to a loss of GR protein. Surprisingly, the amount of GR-bound hsp90 was also unaltered in response to POBA. Taken together, the above observations provide evidence for a novel state of the GR within intact cells in which hsp90 interaction is but one step in the generation or maintenance of hormone- competent receptors. In addition, these results point to the potential use of POBA, and possibly other CaM inhibitors, as antagonists of steroid receptor actions.

This article has been cited by other articles:

				D. M. Presman, E. Hoijman, N. R. Ceballos, M. D. Galigniana, and A. Pecci Melatonin Inhibits Glucocorticoid Receptor Nuclear Translocation in Mouse Thymocytes Endocrinology, November 1, 2006; 147(11): 5452 - 5459. [Abstract] [Full Text] [PDF]

				A. GARCÍA RATO, J. GARCÍA PEDRERO, M. A. MARTÍNEZ, B. DEL RIO, P. S. LAZO, and S. RAMOS Melatonin blocks the activation of estrogen receptor for DNA binding FASEB J, May 1, 1999; 13(8): 857 - 868. [Abstract] [Full Text]

				S. Le Bihan, V. Marsaud, C. Mercier-Bodard, E.-E. Baulieu, S. Mader, J. H. White, and J.-M. Renoir Calcium/Calmodulin Kinase Inhibitors and Immunosuppressant Macrolides Rapamycin and FK506 Inhibit Progestin- and Glucocorticosteroid Receptor-Mediated Transcription in Human Breast Cancer T47D Cells Mol. Endocrinol., July 1, 1998; 12(7): 986 - 1001. [Abstract] [Full Text]

				R. L. Barent, S. C. Nair, D. C. Carr, Y. Ruan, R. A. Rimerman, J. Fulton, Y. Zhang, and D. F. Smith Analysis of FKBP51/FKBP52 Chimeras and Mutants for Hsp90 Binding and Association with Progesterone Receptor Complexes Mol. Endocrinol., March 1, 1998; 12(3): 342 - 354. [Abstract] [Full Text]